Aqtual

Aqtual, Inc. is a Hayward, California precision-medicine company founded in 2019 by Diana Abdueva (Founder and CEO) and co-founder Rich Rava, developing blood-based diagnostics on a proprietary "active chromatin" cell-free DNA (cfDNA) platform. Rather than reading cfDNA for mutations alone, Aqtual captures the previously unexplored cfDNA fragments bound to active chromatin, so a single routine blood draw reports on DNA, epigenetic regulation and protein-DNA binding together — surveying on the order of 200,000 gene promoters, 400,000 enhancers, 50,000 insulators, 20,000 silencers and a million transcription-factor binding sites. Its lead product is a therapy-response prediction test for rheumatoid arthritis, evaluated in the prospective PRIMA-102 observational trial (NCT05936970), with oncology programs in leiomyosarcoma immunotherapy response and early colorectal cancer detection, and stated expansion into immunology, cardiovascular, metabolic and neurological disease. The company raised a USD 16 million Series A in October 2023 and over USD 31 million in Series B funding announced July 2025 from Bold Capital, the Bold Longevity Growth Fund, Genoa Ventures, Manta Ray Ventures and Yu Galaxy. Aqtual is a clinical-diagnostics and life-sciences business, not a software vendor: as of August 2026 it publishes no developer portal, no API documentation and no machine-readable API contract of any kind, and every /.well-known/ and contract-discovery path on aqtual.com returns 404.

Aqtual is profiled on the APIs.io network. Tagged areas include Company, Precision Medicine, Diagnostics, Liquid Biopsy, and Cell-Free DNA.

Aqtual’s developer surface includes engineering blog, support, and 12 more developer resources.

🌐 Visit website 📡 Source on GitHub
9.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-05 · rubric v0.9.1
0 APIs
CompanyPrecision MedicineDiagnosticsLiquid BiopsyCell-Free DNAEpigeneticsGenomicsBiotechnologyOncologyRheumatologyHealth CareUnited States

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-05 · rubric v0.9.1
Composite quality — 9.7/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 1.5 / 12
Discoverability 6.9 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/aqtual: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Aqtual Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Get Started 1

Portal, sign-up, and the first successful call

ClinicalTrial
ClinicalTrial

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Design & Contract 1

Pagination, idempotency, versioning, errors, and events

Conformance
Conformance

Build 1

SDKs, sample code, and the tooling you integrate with

Packages
Packages

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Company 4

The organization behind the API

Website
Website
 Blog
Blog
 Press
Press
 LinkedIn
LinkedIn

Other 4

Properties that don't map to a standard resource type

Publications
Publications
 Team
Team
 PitchBook
PitchBook
 SecondaryMarket
SecondaryMarket

Source (apis.yml)

apis.yml Raw ↑ 
aid: aqtual
name: Aqtual
description: 'Aqtual, Inc. is a Hayward, California precision-medicine company founded in 2019 by Diana Abdueva (Founder and
  CEO) and co-founder Rich Rava, developing blood-based diagnostics on a proprietary "active chromatin" cell-free DNA (cfDNA)
  platform. Rather than reading cfDNA for mutations alone, Aqtual captures the previously unexplored cfDNA fragments bound
  to active chromatin, so a single routine blood draw reports on DNA, epigenetic regulation and protein-DNA binding together
  — surveying on the order of 200,000 gene promoters, 400,000 enhancers, 50,000 insulators, 20,000 silencers and a million
  transcription-factor binding sites. Its lead product is a therapy-response prediction test for rheumatoid arthritis, evaluated
  in the prospective PRIMA-102 observational trial (NCT05936970), with oncology programs in leiomyosarcoma immunotherapy response
  and early colorectal cancer detection, and stated expansion into immunology, cardiovascular, metabolic and neurological
  disease. The company raised a USD 16 million Series A in October 2023 and over USD 31 million in Series B funding announced
  July 2025 from Bold Capital, the Bold Longevity Growth Fund, Genoa Ventures, Manta Ray Ventures and Yu Galaxy. Aqtual is
  a clinical-diagnostics and life-sciences business, not a software vendor: as of August 2026 it publishes no developer portal,
  no API documentation and no machine-readable API contract of any kind, and every /.well-known/ and contract-discovery path
  on aqtual.com returns 404.'
url: https://raw.githubusercontent.com/api-evangelist/aqtual/refs/heads/main/apis.yml
image: https://aqtual.com/apple-touch-icon-152x152.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Precision Medicine
- Diagnostics
- Liquid Biopsy
- Cell-Free DNA
- Epigenetics
- Genomics
- Biotechnology
- Oncology
- Rheumatology
- Health Care
- United States
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-08-02'
  status: enriched
  artifacts_added: 5
  pass: local-v1
common:
- type: Website
  url: https://aqtual.com/
- type: Blog
  url: https://aqtual.com/blog/
- type: Press
  url: https://aqtual.com/newsroom/
- type: Publications
  url: https://aqtual.com/publications/
- type: Team
  url: https://aqtual.com/team/
- type: Support
  url: mailto:media@aqtual.com
- type: LinkedIn
  url: https://www.linkedin.com/company/aqtual
- type: PitchBook
  url: https://pitchbook.com/profiles/company/470599-39
- type: SecondaryMarket
  url: https://forgeglobal.com/aqtual_stock/
- type: ClinicalTrial
  url: https://clinicaltrials.gov/study/NCT05936970
- type: DomainSecurity
  url: security/aqtual-domain-security.yml
- type: Packages
  url: packages/aqtual-packages.yml
- type: Conformance
  url: conformance/aqtual-conformance.yml
- type: LLMsTxt
  url: llms/aqtual-llms.txt